Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Currently, 25 states and Washington DC have enacted full medical marijuana (MMJ) programs while 18 states allow limited access to MMJ products. Limited access states permit low (or zero) tetrahydrocannabinol (THC) and high cannabidiol (CBD) products to treat specified conditions such as uncontrolled epilepsy. Although MMJ products are derived from the same plant species as recreational MJ, they are often selected for their unique cannabinoid constituents and ratios, not typically sought by recreational users, which may impact neurocognitive outcomes. To date, few studies have investigated the potential impact of MMJ use on cognitive performance, despite a well-documented association between recreational marijuana (MJ) use and executive dysfunction. The current study assessed the impact of 3 months of MMJ treatment on executive function, exploring whether MMJ patients would experience improvement in cognitive functioning, perhaps related to primary symptom alleviation. As part of a larger longitudinal study, 24 patients certified for MMJ use completed baseline executive function assessments and 11 of these so far have returned for their first follow-up visit 3 months after initiating treatment. Results suggest that in general, MMJ patients experienced some improvement on measures of executive functioning, including the Stroop Color Word Test and Trail Making Test, mostly reflected as increased speed in completing tasks without a loss of accuracy. On self-report questionnaires, patients also indicated moderate improvements in clinical state, including reduced sleep disturbance, decreased symptoms of depression, attenuated impulsivity, and positive changes in some aspects of quality of life. Additionally, patients reported a notable decrease in their use of conventional pharmaceutical agents from baseline, with opiate use declining more than 42%. While intriguing, these findings are preliminary and warrant further investigation at additional time points and in larger sample sizes. Given the likelihood of increased MMJ use across the country, it is imperative to determine the potential impact of short- and long-term treatment on cognitive performance as well as the efficacy of MMJ treatment itself.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 1×
“…MMJ use, consistent with other recent reports that have also demonstrated varying degrees of efficacy of cannabinoidbased therapies (Boychuk et al., 2015; Deshpande et al., 2015; Press et al., 2015; Whiting et al., 2015; Devinsky et al., 2016; Haroutounian et al., 2016; Wilkie et al., 2016).”
ResultPersistent cannabis users show neuropsychological decline from childhood to midlife
Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S. E., McDonald, K., Ward, A., Poulton, R., & Moffitt, T. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206820109 · Cited by 1,523
The effect of pain on cognitive function: A review of clinical and preclinical research
Moriarty, O., McGuire, B. E., & Finn, D. P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.002 · Cited by 1,122
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Crean, R. D., Crane, N. A., & Mason, B. J. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31820c23fa · Cited by 732 · cited 5×
“It is also possible that MMJ products themselves protect against the executive function deficits that have been widely reported in recreational MJ users (for review see Crean et al., 2011).”
BackgroundResultInfluentialBhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Practice effects and the use of alternate forms in serial neuropsychological testing
BEGLINGER, L., GAYDOS, B., TANGPHAODANIELS, O., DUFF, K., KAREKEN, D., CRAWFORD, J., FASTENAU, P., & SIEMERS, E. (2005) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2004.12.003 · Cited by 362 · cited 2×
“For example, a study of practice effects in serial neuropsychological testing found no effects on the Letter Number Sequencing and Trail Making tasks even with weekly administration (Beglinger et al., 2005)—a much more frequent schedule of testing than utilized in the current study.”
BackgroundCannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305 · cited 1×
“In another study of acute administration of CBD in recreational MJ users who smoked once a month for at least a year, Morgan et al. (2010) reported that those who smoked MJ strains low in CBD performed worse on a verbal memory task than those who smoked MJ strains high in CBD. Similarly, an…”
Background
Research works printed but not linked: 80
- ArcView Market Research, 2016, The State of Legal Marijuana Markets, 2nd Edn.
- Auer, 2016, Association between lifetime marijuana use and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study, JAMA Intern. Med., 176, 352, 10.1001/jamainternmed.2015.7841 · DOI · Paper page
- Ballantyne, 2008, Efficacy of opioids for chronic pain: a review of the evidence, Clin. J. Pain, 24, 469, 10.1097/AJP.0b013e31816b2f26 · DOI · Paper page
- Baron, 2015, Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been .…, Headache, 55, 885, 10.1111/head.12570 · DOI · Paper page
- Beck, 1990, Manual for the Beck Anxiety Inventory
- Beck, 1961, An inventory for measuring depression, Arch. Gen. Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
- Becker, 2014, Neurocognition in college-aged daily marijuana users, J. Clin. Exp. Neuropsychol., 36, 379, 10.1080/13803395.2014.893996 · DOI · Paper page
- Berg, 1948, A simple objective technique for measuring flexibility in thinking, J. Gen. Psychol., 39, 15, 10.1080/00221309.1948.9918159 · DOI · Paper page
- Birch, 1889, The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning, Lancet, 133, 625, 10.1016/S0140-6736(00)30567-0 · DOI
- Blessing, 2015, Cannabidiol as a potential treatment for anxiety disorders, Neurotherapeutics, 12, 825, 10.1007/s13311-015-0387-1 · DOI · Paper page
- Booth, 2003, Cannabis: A History
- Borelli, 2013, Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease, Biochem. Pharmacol., 85, 1306, 10.1016/j.bcp.2013.01.017 · DOI · Paper page
- Borgwardt, 2008, Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition, Biol. Psychiatry, 64, 966, 10.1016/j.biopsych.2008.05.011 · DOI · Paper page
- Boychuk, 2015, The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review, J. Oral Facial Pain Headache, 29, 7, 10.11607/ofph.1274 · DOI · Paper page
- Braga, 2012, Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder, Psychiatry Res., 200, 242, 10.1016/j.psychres.2012.05.025 · DOI
- Buysse, 1989, The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research, Psychiatry Res., 28, 193, 10.1016/0165-1781(89)90047-4 · DOI · Paper page
- Center for Behavioral Health Statistics Quality, 2015, Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50)
- Centers for Disease Control Prevention, 2015, Number and Age-Adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014
- Consroe, 1991, Controlled clinical trial of cannabidiol in Huntington's disease, Pharmacol. Biochem. Behav., 40, 701, 10.1016/0091-3057(91)90386-G · DOI · Paper page
- Cousijn, 2013, Cannabis dependence, cognitive control and attentional bias for cannabis words, Addict. Behav., 38, 2825, 10.1016/j.addbeh.2013.08.011 · DOI
- Crane, 2013, Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users, J. Int. Neuropsychol. Soc., 19, 1009, 10.1017/S135561771300088X · DOI · Paper page
- Crane, 2015, Neuropsychological sex differences associated with age of initiated use among young adult cannabis users, J. Clin. Exp. Neuropsychol., 37, 389, 10.1080/13803395.2015.1020770 · DOI · Paper page
- Dahlgren, 2016, Marijuana use predicts cognitive performance on tasks of executive function, J. Stud. Alcohol Drugs, 77, 298, 10.15288/jsad.2016.77.298 · DOI
- Degenhardt, 2015, Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study, Drug Alcohol Depend., 147, 144, 10.1016/j.drugalcdep.2014.11.031 · DOI · Paper page
- Department of Justice, 2016a, Denial of Petition to Initiate Proceedings to Reschedule Marijuana
- Department of Justice, 2016b, Applications to Become Registered Under the Controlled Substances Act to Manufacture Marijuana to Supply Researchers in the United States (21 CFR Part 1301, Docket No. DEA-447)
- Deshpande, 2015, Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials, Can. Fam. Physician, 61, E372
- Dougherty, 2013, Impulsivity, attention, memory, and decision-making among adolescent marijuana users, Psychopharmacology (Berl)., 226, 307, 10.1007/s00213-012-2908-5 · DOI · Paper page
- Ehrenreich, 1999, Specific attentional dysfunction in adults following early start of cannabis use, Psychopharmacology (Berl)., 142, 295, 10.1007/s002130050892 · DOI · Paper page
- Eisenberg, 2014, The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study, J. Pain Palliat. Care Pharmacother., 28, 216, 10.3109/15360288.2014.941130 · DOI
- ElSohly, 2016, Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States, Biol. Psychiatry, 79, 613, 10.1016/j.biopsych.2016.01.004 · DOI · Paper page
- Englund, 2013, Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, J. Psychopharmacol., 27, 19, 10.1177/0269881112460109 · DOI · Paper page
- Englund, 2016, The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial, J. Psychopharmacol. (Oxford)., 30, 140, 10.1177/0269881115615104 · DOI · Paper page
- Flachenecker, 2014, Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice–results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity, Eur. Neurol., 71, 271, 10.1159/000357427 · DOI · Paper page
- Fontes, 2011, Cannabis use before age 15 and subsequent executive functioning, Br. J. Psychiatry, 198, 442, 10.1192/bjp.bp.110.077479 · DOI · Paper page
- Fried, 2005, Neurocognitive consequences of marihuana–a comparison with pre-drug performance, Neurotoxicol. Teratol., 27, 231, 10.1016/j.ntt.2004.11.003 · DOI · Paper page
- Giacoppo, 2015, Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis, Eur. Rev. Med. Pharmacol. Sci., 19, 4906
- Giedd, 1999, Brain development during childhood and adolescence: a longitudinal MRI study, Nat. Neurosci., 2, 861, 10.1038/13158 · DOI · Paper page
- Grinspoon, 1997, Marihuana: The Forbidden Medicine
- Gruber, 2012b, Age of onset of marijuana use impacts inhibitory processing, Neurosci. Lett., 511, 89, 10.1016/j.neulet.2012.01.039 · DOI · Paper page
- Gruber, 2012a, Age of onset of marijuana use and executive function, Psychol. Addict. Behav., 26, 496, 10.1037/a0026269 · DOI · Paper page
- Gul, 2015, Practice and colour-word integration in Stroop interference, Psicológica, 36, 37
- Hanson, 2014, Adolescent marijuana users have elevated risk-taking on the balloon analog risk task, J. Psychopharmacol. (Oxford)., 28, 1080, 10.1177/0269881114550352 · DOI
- Izzo, 2012, Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice, Br. J. Pharmacol., 166, 1444, 10.1111/j.1476-5381.2012.01879.x · DOI · Paper page
- Jackson, 2016, Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies, Proc. Natl. Acad. Sci. U.S.A., 113, E500, 10.1073/pnas.1516648113 · DOI · Paper page
- Jacobus, 2015, Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: a three-year longitudinal study, Neuropsychology, 29, 829, 10.1037/neu0000203 · DOI · Paper page
- Jacobus, 2014, Effects of cannabis on the adolescent brain, Curr. Pham. Des., 20, 2186, 10.2174/13816128113199990426 · DOI · Paper page
- Johnston, 2015, Monitoring the Future National Survey Results on Drug Use: 1975-2015: Overview: Key Findings on Adolescent Drug Use.
- Joy, 1999, Marijuana and Medicine: Assessing the Science Base
- Lezak, 2004, Neuropsychological Assessment, 4th Edn
- Lisdahl, 2012, Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults, J. Int. Neuropsychol. Soc., 18, 678, 10.1017/S1355617712000276 · DOI · Paper page
- MacLeod, 1991, Half a century of research on the stroop effect: an integrative review, Psychol. Bull., 109, 163, 10.1037/0033-2909.109.2.163 · DOI · Paper page
- Medina, 2007, Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence, J. Int. Neuropsychol. Soc., 13, 807, 10.1017/S1355617707071032 · DOI · Paper page
- Mokrysz, 2016, Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study, J. Psychopharm., 30, 159, 10.1177/0269881115622241 · DOI · Paper page
- Patti, 2016, Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity, J. Neurol Neurosurg. Psychiatry., 87, 944, 10.1136/jnnp-2015-312591 · DOI · Paper page
- Patton, 1995, Factor structure of the Barratt impulsiveness scale, J. Clin. Psychol., 51, 768, 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1 · DOI · Paper page
- Pope, 2003, Early-onset cannabis use and cognitive deficits: what is the nature of the association?, Drug Alcohol Depend., 69, 303, 10.1016/S0376-8716(02)00334-4 · DOI · Paper page
- Potter, 1917, Cannabis, 195
- Press, 2015, Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, Epilepsy Behav., 45, 49, 10.1016/j.yebeh.2015.02.043 · DOI · Paper page
- Ringen, 2010, Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia, Psychol. Med., 40, 1337, 10.1017/S0033291709991620 · DOI · Paper page
- Rosenblum, 2008, Opioids and the treatment of chronic pain: controversies, current status, and future directions, Exp. Clin. Psychopharmacol., 16, 405, 10.1037/a0013628 · DOI · Paper page
- Ryan-Ibarra, 2015, Prevalence of medical marijuana use in California, 2012, Drug Alcohol Rev., 34, 141, 10.1111/dar.12207 · DOI
- Sagar, 2015, The impact of initiation: early onset marijuana smokers demonstrate altered Stroop performance and brain activation, Dev. Cogn. Neurosci., 16, 84, 10.1016/j.dcn.2015.03.003 · DOI · Paper page
- Sagar, 2016, Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood, PLoS ONE, 11, e0157060, 10.1371/journal.pone.0157060 · DOI
- Shinjyo, 2013, The effect of cannabichromene on adult neural stem/progenitor cells, Neurochem. Int., 63, 432, 10.1016/j.neuint.2013.08.002 · DOI
- Shuster, 2016, Early onset marijuana use is associated with learning inefficiencies, Neuropsychology, 30, 405, 10.1037/neu0000281 · DOI
- Silver, 2016, Marijuana's $40 Billion Dollar Green Rush, Forbes
- Sobell, 1998, Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations, Br. J. Addict., 83, 393, 10.1111/j.1360-0443.1988.tb00485.x · DOI · Paper page
- Solowij, 2012, Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents, Psychopharmacology (Berl)., 219, 575, 10.1007/s00213-011-2486-y · DOI
- Tait, 2011, Cannabis use and cognitive function: 8-year trajectory in a young adult cohort, Addiction, 106, 2195, 10.1111/j.1360-0443.2011.03574.x · DOI · Paper page
- Tamm, 2013, Impact of ADHD and cannabis use on executive functioning in young adults, Drug Alcohol Depend., 133, 607, 10.1016/j.drugalcdep.2013.08.001 · DOI · Paper page
- Therapeutic Hemp Medical Access Act, 2015, Therapeutic Hemp Medical Access Act of
- Vytal, 2013, The complex interaction between anxiety and cognition: insight from spatial and verbal working memory, Front. Hum. Neurosci., 7, 10.3389/fnhum.2013.00093 · DOI · Paper page
- Wachtel, 2002, Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans, Psychopharmacology (Berl)., 161, 331, 10.1007/s00213-002-1033-2 · DOI · Paper page
- Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med. Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
- Wechsler, 1997, Wechsler Adult Intelligence Scale, 3rd Edn. (WAIS-III)
- Wechsler, 1999, Wechsler Abbreviated Scale of Intelligence
- Wilkie, 2016, Medical marijuana use in oncology: a review, JAMA Oncol., 10.1001/jamaoncol.2016.0155 · DOI · Paper page
- Winward, 2014, Heavy alcohol use, marijuana use, and concomitant use by adolescents are associated with unique and shared cognitive decrements, J. Int. Neuropsychol. Soc., 20, 784, 10.1017/S1355617714000666 · DOI · Paper page
- Zeiger, 2010, Subjective effects to marijuana associated with marijuana use in community and clinical subjects, Drug Alcohol Depend., 109, 161, 10.1016/j.drugalcdep.2009.12.026 · DOI
Cited by
Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0335 · Cited by 391
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253
Burggren, A. C., Shirazi, A., Ginder, N., & London, E. D. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1634086 · Cited by 144
Metadata
- Authors
- Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M. T., Smith, R. T., & Lukas, S. E.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2016-10-13
- Volume
- 7
- Pages
- 355-355
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2531714917
- Cited by
- 79
- References
- 19
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.